Cytotoxic T Lymphocyte Antigen 4 (CTLA4) is a glycoprotein expressed on the surface of activated T cells; it acts as a potent inhibitor of the cytotoxic T lymphocyte activation and thus a key negative regulator of anti-tumor activity. Thus, Anti-CTLA4 immunotherapy is highly effective at reactivating T cell responses against cancer, in particular melanoma. In the present study, the researchers show that CTLA-4 is also highly expressed by most human melanoma cell lines. Also, the researchers checked by RNA sequencing the upregulation of genes downstream of molecular cascades triggered by CTLA-4. Taken together, the results raise the possibility that CTLA-4 targeting on melanoma cells may contribute to the clinical immunobiology of anti-CTLA-4 responses.
Interferon-gamma signaling in melanocytes and melanoma cells regulates expression of CTLA-4
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!